Celcuity Inc. Reports Encouraging Q3 2025 Results: A Step Towards FDA Approval

Ticker: CELC | Date: November 12, 2025

Financial Performance Overview

Celcuity Inc., the clinical-stage biotechnology company known for its targeted therapies in oncology, recently announced its financial results for the third quarter ended September 30, 2025. While the precise details on EPS (earnings per share) and revenue forecast were not disclosed in the announcement, the company has been making strides that suggest a promising trajectory.

Key Developments and Clinical Progress

During the recent European Society for Medical Oncology (ESMO) Congress, Celcuity presented significant efficacy and safety results from the PIK3CA wild-type cohort of its Phase 3 VIKTORIA-1 clinical trial. This late-breaking oral presentation is a noteworthy highlight, as it showcases the potential of their drug gedatolisib in treating advanced breast cancer.

The company also revealed plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for gedatolisib based on the promising data from the PIK3CA wild-type cohort, aiming for completion by the fourth quarter of 2025. Such proactive steps could lead to an earnings surprise, significantly boosting investor confidence.

Management's Insights

Brian Sullivan, CEO and co-founder of Celcuity, expressed optimism regarding their clinical and regulatory progress. “We made significant clinical and regulatory progress in the third quarter,” he stated, emphasizing the urgency for more effective therapies for patients with HR+, HER2- advanced breast cancer. His comments hint at a larger narrative of innovation and responsiveness in a competitive biotech landscape.

Looking Ahead: What This Means for Celcuity and Its Peers

With the PIK3CA mutant cohort of the VIKTORIA-1 trial fully enrolled and topline data expected in late Q1 or Q2 2026, investors have a lot to look forward to. Should the FDA approval come through, it may not just reshape Celcuity’s market position but also set a new standard for competitors in the oncology space.

Moreover, the company’s strengthened balance sheet, coupled with the potential for groundbreaking results, puts them in an enviable position to capitalize on this momentum. It’s a classic case of “good news travels fast”—and in this sector, the right kind of news can lead to a stock price surge. Investors will be keenly watching for the next EPS consensus and any shifts in revenue forecasts as the NDA submission approaches.